A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Dabrafenib Impurity 29 - Request Quote

Picture of Dabrafenib Impurity 29

Dabrafenib Impurity 29

SZ CAT No:SZ-D120045
CAS No
NA
Mol.F.
C23H21F2N5O3S2
Mol.Wt.
517.6
Inv. Status
Synthesis on demand

Chemical Name :

Shipping Temperature :

HSN Code :

Country of Origin :

Smiles :

Usage Note:

Dabrafenib Impurity 29 is chemically N-(3-(5-(2-Aminopyrimidin-4-yl)-2-(tert-butyl)thiazol-4-yl)-2-fluorophenyl)-2-fluoro-6-hydroxybenzenesulfonamide. Dabrafenib Impurity 29 is supplied with detailed characterization data compliant with regulatory guideline. Dabrafenib Impurity 29 can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Dabrafenib.

The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.

Applications & Regulatory Use Cases

buy high quality Dabrafenib Impurity 29

Purchase Dabrafenib Impurity 29

Dabrafenib Impurity 29 suppliers

Dabrafenib Impurity 29 manufacturers

Dabrafenib Impurity 29 price

Order Dabrafenib Impurity 29

Enquire Dabrafenib Impurity 29

Dabrafenib Impurity 29 cost

Dabrafenib Impurity 29 Supplier

Dabrafenib Impurity 29 Distributor

Dabrafenib Impurity 29 for Method Validation

Dabrafenib Reference Standard

Dabrafenib Impurity 29 for ANDA Filing

Dabrafenib Impurity 29 for Forced Degradation Studies

Dabrafenib Impurity 29 Identification Standards

Dabrafenib Impurity 29 for DMF Filing

ℹ️

Disclaimer

SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.

SynZeal will update these details as per new developments or findings in product specifications without further notice.

,